Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025

mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma

10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab

Sun Pharma to present results of the Phase III PIVOTAL trial of Nidlegy in melanoma at ASCO 2024

PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy

USFDA approves Opdualag to treat metastatic melanoma

Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab

Merck’s KEYTRUDA demonstrates extended relief for patients with resected stage IIB and IIC melanoma

New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients

Zydus signs exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India

ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy

The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies

Bristol Myers Squibb showcases transformative advances across oncology portfolio at ESMO 2025

Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy

This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program

Philogen withdraws marketing authorization application for Nidlegy in EU

The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls